Trials / Recruiting
RecruitingNCT07292038
Safety and Pharmacokinetics of NM6603 in Chinese Patients With Advanced Solid Tumors
A Phase I, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of NM6603 in Patients With Advanced Solid Tumors
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- NucMito Pharmaceuticals Co. Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study is to assess the MTD and PK of NM6603 in adult patients with advanced solid tumors.
Detailed description
This is a Phase 1, open label, 3+3 dose escalation study designed to evaluate the safety profile, the maximum tolerated dose (MTD), the pharmacokinetic and the preliminary antitumor activity of NM6603 in patients with advanced solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | NM6603 | NM6603 is an orally administered investigational small-molecule drug evaluated in this dose-escalation study in patients with advanced solid tumors. |
Timeline
- Start date
- 2025-12-18
- Primary completion
- 2026-11-01
- Completion
- 2026-11-01
- First posted
- 2025-12-18
- Last updated
- 2026-01-14
Locations
3 sites across 1 country: China
Source: ClinicalTrials.gov record NCT07292038. Inclusion in this directory is not an endorsement.